Next early phase destinations

There has been a continuous increase in the conduct of Phase I trials in emerging destinations of Australia, China, Russia, Singapore and South Korea. Though developed markets of North America and Europe hold greater than 70% of the complex Phase I trials, majority of the Phase I bioequivalence and certain special population FIH studies are carried out in emerging countries of the Asia Pacific region. Now that the emerging countries are identified, the next phase would be to decide on the market to enter. During this phase, there is a prerequisite to understand the key parameters that needs to be taken into consideration while making a sourcing decision involving low cost country outsourcing. This paper will evaluate the crucial parameters for each country within the phase I emerging markets and arrive at the next best destinations for early phase clinical trial outsourcing.